<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432560</url>
  </required_header>
  <id_info>
    <org_study_id>MIDAS</org_study_id>
    <secondary_id>1U54HL127672</secondary_id>
    <nct_id>NCT02432560</nct_id>
  </id_info>
  <brief_title>Safety and Durability of Sirolimus for Treatment of LAM</brief_title>
  <acronym>MIDAS</acronym>
  <official_title>Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MIDAS study aims to follow women with LAM who are currently taking, have previously
      failed or been intolerant of, or are considering treatment with mTOR inhibitors sirolimus or
      everolimus as part of their clinical care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphangioleiomyomatosis (LAM) is an uncommon disease affecting women. It is associated with
      cystic lung destruction and progressive respiratory failure. The Multicenter International
      LAM Efficacy of Sirolimus (MILES) Trial, led by the investigators' research team,
      demonstrated that mTOR (mammalian target of rapamycin) inhibition with sirolimus was an
      effective therapy that stabilized decline in FEV1 (forced expiratory volume). However, lung
      function decline resumed when the drug was stopped at the one year point in MILES, suggesting
      that therapy is suppressive rather than remission-inducing, and may need to be lifelong. The
      investigators therefore need to know whether long-term therapy with sirolimus is safe and
      effective. To accomplish this goal, the investigators will conduct the Multicenter
      International Durability and Safety of Sirolimus in LAM Trial (MIDAS). This is an
      observational &quot;registry&quot; trial. The investigators propose to enroll 300 LAM patients who are
      on, have previously failed or been intolerant of or are considering taking sirolimus or
      everolimus for clinical reasons in a longitudinal observational study. This registry will
      follow lung function tests and adverse events over periods of at least 2 years. The mTOR
      inhibitor therapy will be initiated and managed by the participant's clinician. The study is
      planned to use the collected data from standard of care. This study will help us to refine
      treatment for patients with LAM and determine if long term suppressive therapy with sirolimus
      can prevent progression to later stages of disease. This research will be accomplished as
      part of the Rare Lung Disease Clinical Network Consortium, with data stored and analyzed by
      the Database Management Coordinating Center (DMCC) as part of the NIH-supported Rare Disease
      Consortium.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (subjects will collect symptoms in diary)</measure>
    <time_frame>2 years</time_frame>
    <description>subjects will collect symptoms in diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - FEV1 slope</measure>
    <time_frame>2 years</time_frame>
    <description>forced expiratory volume (FEV1) slope over 2 years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy -10% reduction in FEV1</measure>
    <time_frame>2 years</time_frame>
    <description>time to 10% reduction in FEV1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - 10% reduction in FVC1</measure>
    <time_frame>2 years</time_frame>
    <description>time to 10% reduction in FVC (forced vital capacity) as compared to the placebo group from the MILES trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - annual change in spirometry</measure>
    <time_frame>2 years</time_frame>
    <description>absolute annual change in spirometry [FEV1, FVC, TLC (total lung capacity), RV (residual volume) and diffusing capacity]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>Euro VAS Scale for QoL, Fatigue, and Dyspnea, Shortness of Breath Questionnaire, ATAQ-LAM Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Performance (St. George's Respiratory Questionnaire, Functional Performance Inventory)</measure>
    <time_frame>2 years</time_frame>
    <description>St. George's Respiratory Questionnaire, Functional Performance Inventory</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lymphangioleiomyomatosis</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <description>women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking everolimus as part of their clinical care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <description>women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking sirolimus as part of their clinical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Rapamune, rapamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Rare Lung Disease Clinical Network Consortium Clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, age 18 or over

          -  Diagnosis of LAM

          -  Signed and dated informed consent

          -  On chronic therapy, newly treated or may be considered for therapy with mTOR
             inhibitors or previously intolerant of or having failed mTOR inhibitor therapy

        Exclusion Criteria:

          -  Inability to attend at least one RLD Clinic visit per year

          -  Inability to give informed consent

          -  Inability or unwillingness to perform pulmonary function testing
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis X McCormack, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francis X McCormack, MD</last_name>
    <phone>(513) 558-0588</phone>
    <email>frank.mccormack@uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan McMahan, BSN, RN</last_name>
    <phone>(513) 558-4376</phone>
    <email>susan.mcmahan@uc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Barney, MD</last_name>
      <phone>205-996-9405</phone>
      <email>drbarney@uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Ruoss, MD</last_name>
      <phone>650-723-6381</phone>
      <email>ruoss@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Downey, MD</last_name>
      <phone>303-398-1436</phone>
      <phone_ext>1881</phone_ext>
      <email>gregory.downey@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Burger, MD</last_name>
      <phone>904-953-2381</phone>
      <email>charles.burger@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sirhari Veeraraghavan, MD</last_name>
      <email>veeraraghavan@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center, Chicago</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Dilling, MD</last_name>
      <phone>708-216-4946</phone>
      <email>ddillin@lumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joel Moss, MD</last_name>
      <phone>301-496-3632</phone>
      <email>mossj@nhlbi.nih.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Henske, MD</last_name>
      <phone>617-355-9049</phone>
      <email>ehenske@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Lan Han, MD</last_name>
      <phone>734-936-5047</phone>
      <email>mrking@umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Ryu, MD</last_name>
      <phone>507-284-2447</phone>
      <email>ryu.jay@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Shifren, MD</last_name>
      <phone>314-362-6904</phone>
      <email>ashifren@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeanine D'Armiento, MD</last_name>
      <phone>212-305-3745</phone>
      <email>jmd12@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-8692</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Sime, MD</last_name>
      <phone>585-275-4161</phone>
      <email>patricia_sime@urmc.rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan McMahan, BSN, RN</last_name>
      <phone>513-558-4376</phone>
      <email>susan.mcmahan@uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Parambil, MD</last_name>
      <phone>216-444-4222</phone>
      <email>PARAMBJ@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Robert Kotloff, MD</last_name>
      <email>kotlofr@ccf.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Barker, MD</last_name>
      <phone>503-494-7680</phone>
      <email>barkera@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Kreider, MD</last_name>
      <phone>215-349-5488</phone>
      <email>maryelizabeth.kreider@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlie Strange, MD</last_name>
      <phone>843-792-2153</phone>
      <email>strangec@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Young, MD</last_name>
      <phone>615-343-4761</phone>
      <email>lisa.young@Vanderbilt.Edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Girod, MD</last_name>
      <phone>214-648-9095</phone>
      <email>Carlos.Girod@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalid Almoosa, MD</last_name>
      <phone>832-325-7222</phone>
      <email>Khalid.F.Almoosa@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Paine, MD</last_name>
      <phone>801-581-7806</phone>
      <email>Robert.Paine@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Pappas, MD</last_name>
      <phone>206-320-6500</phone>
      <email>george.pappas@minorandjames.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Francis McCormack</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Lymphangioleiomyomatosis</keyword>
  <keyword>LAM</keyword>
  <keyword>rare lung</keyword>
  <keyword>Rare Lung Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphangioleiomyomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

